Abstract Details Title Remarkable Benefit Persisting Undiminished for 8 Years after Stopping 14 Years of Interferon-[alpha]2A (Inf-[alpha]) Treatment of Fever-Responsive Dysimmune Neuropathy (FRDN): Possibly a Combined Antidysimmune Plus Antiviral Effect, and Thus a Putative Model for Future "Combined Antidysimmune" Therapies Topic Peripheral Nerve Presentation(s) (-) Poster/Presentation Number 231 Objective Background Design/Methods Results Conclusions Authors/Disclosures W. K. Engel, MD, FÂ鶹´«Ã½Ó³» No disclosure on file No disclosure on file